Literature DB >> 8243674

Carbohydrate isoforms of antithrombin variant N135Q with different heparin affinities.

I V Turko1, B Fan, P G Gettins.   

Abstract

We have changed one of the carbohydrate-bearing asparagine residues of human antithrombin to glutamine by site-directed mutagenesis and expressed the variant antithrombin, N135Q, in baby hamster kidney cells. Two isoforms were secreted, both of which had higher affinity for heparin than human plasma alpha antithrombin. Both forms had normal inhibitory activity toward factor Xa and showed normal heparin acceleration of proteinase inhibition. The mutation resulted in a higher production of the very high affinity form from about 30% to 60% of the total secreted antithrombin. This form should be the most useful for comparison of the effects of other mutations on heparin binding and proteinase inhibition.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8243674     DOI: 10.1016/0014-5793(93)80429-x

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

1.  Elimination of glycosylation heterogeneity affecting heparin affinity of recombinant human antithrombin III by expression of a beta-like variant in baculovirus-infected insect cells.

Authors:  E Ersdal-Badju; A Lu; X Peng; V Picard; P Zendehrouh; B Turk; I Björk; S T Olson; S C Bock
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

2.  The allosteric mechanism of activation of antithrombin as an inhibitor of factor IXa and factor Xa: heparin-independent full activation through mutations adjacent to helix D.

Authors:  Alexey Dementiev; Richard Swanson; Ryan Roth; Giulia Isetti; Gonzalo Izaguirre; Steven T Olson; Peter G W Gettins
Journal:  J Biol Chem       Date:  2013-09-25       Impact factor: 5.157

3.  A Comprehensive Docking and MM/GBSA Rescoring Study of Ligand Recognition upon Binding Antithrombin.

Authors:  Xiaohua Zhang; Horacio Perez-Sanchez; Felice C Lightstone
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.